WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H112155
CAS#: 22368-21-4
Description: Eupatilin inhibits cell growth in A375 melanoma cells.
Hodoodo Cat#: H112155
Name: Eupatilin
CAS#: 22368-21-4
Chemical Formula: C18H16O7
Exact Mass: 344.09
Molecular Weight: 344.320
Elemental Analysis: C, 62.79; H, 4.68; O, 32.53
Synonym: Eupatilin; NSC 122413; NSC122413; NSC-122413
IUPAC/Chemical Name: 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxy-4H-chromen-4-one
InChi Key: DRRWBCNQOKKKOL-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H16O7/c1-22-12-5-4-9(6-14(12)23-2)13-7-10(19)16-15(25-13)8-11(20)18(24-3)17(16)21/h4-8,20-21H,1-3H3
SMILES Code: O=C1C2=C(C(OC)=C(C=C2OC(C3=CC=C(C(OC)=C3)OC)=C1)O)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMF | 50.0 | 145.21 | |
| DMSO | 33.0 | 95.84 |
The following data is based on the product molecular weight 344.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Park SJ, Choi H, Kim JH, Kim CS. Antifibrotic effects of eupatilin on TGF-β1-treated human vocal fold fibroblasts. PLoS One. 2021 Mar 25;16(3):e0249041. doi: 10.1371/journal.pone.0249041. PMID: 33765087; PMCID: PMC7993872.
2: Lou Y, Wu J, Liang J, Yang C, Wang K, Wang J, Guo X. Eupatilin protects chondrocytes from apoptosis via activating sestrin2-dependent autophagy. Int Immunopharmacol. 2019 Oct;75:105748. doi: 10.1016/j.intimp.2019.105748. Epub 2019 Jul 12. PMID: 31306979.
3: Cinar AK, Ozal SA, Serttas R, Erdogan S. Eupatilin attenuates TGF-β2-induced proliferation and epithelial-mesenchymal transition of retinal pigment epithelial cells. Cutan Ocul Toxicol. 2021 Jun;40(2):103-114. doi: 10.1080/15569527.2021.1902343. Epub 2021 Apr 8. PMID: 33719768.
4: Lee M, Yang C, Song G, Lim W. Eupatilin Impacts on the Progression of Colon Cancer by Mitochondria Dysfunction and Oxidative Stress. Antioxidants (Basel). 2021 Jun 15;10(6):957. doi: 10.3390/antiox10060957. PMID: 34203665; PMCID: PMC8232173.
5: Wu Z, Zou B, Zhang X, Peng X. Eupatilin regulates proliferation and cell cycle of cervical cancer by regulating hedgehog signalling pathway. Cell Biochem Funct. 2020 Jun;38(4):428-435. doi: 10.1002/cbf.3493. Epub 2020 Jan 11. PMID: 31926121.
6: Sun Y, Ge J, Tang W, Hong H, Liu D, Lin J. Hsa_circ_0045714 induced by eupatilin has a potential to promote fracture healing. Biofactors. 2021 May;47(3):376-385. doi: 10.1002/biof.1707. Epub 2021 Jan 25. PMID: 33496034.
7: Liu H, Hao J, Wu C, Liu G, Wang X, Yu J, Liu Y, Zhao H. Eupatilin Alleviates Lipopolysaccharide-Induced Acute Lung Injury by Inhibiting Inflammation and Oxidative Stress. Med Sci Monit. 2019 Nov 4;25:8289-8296. doi: 10.12659/MSM.917406. PMID: 31680664; PMCID: PMC6854882.
8: Li YY, Wu H, Dong YG, Lin BO, Xu G, Ma YB. Application of eupatilin in the treatment of osteosarcoma. Oncol Lett. 2015 Oct;10(4):2505-2510. doi: 10.3892/ol.2015.3563. Epub 2015 Aug 4. PMID: 26622880; PMCID: PMC4580008.
9: Fei X, Wang J, Chen C, Ding B, Fu X, Chen W, Wang C, Xu R. Eupatilin inhibits glioma proliferation, migration, and invasion by arresting cell cycle at G1/S phase and disrupting the cytoskeletal structure. Cancer Manag Res. 2019 May 24;11:4781-4796. doi: 10.2147/CMAR.S207257. PMID: 31213900; PMCID: PMC6539175.
10: Zhang Y, Qin L, Xie J, Li J, Wang C. Eupatilin prevents behavioral deficits and dopaminergic neuron degeneration in a Parkinson's disease mouse model. Life Sci. 2020 Jul 15;253:117745. doi: 10.1016/j.lfs.2020.117745. Epub 2020 May 3. PMID: 32376269.
11: Song EH, Chung KS, Kang YM, Lee JH, Lee M, An HJ. Eupatilin suppresses the allergic inflammatory response in vitro and in vivo. Phytomedicine. 2018 Mar 15;42:1-8. doi: 10.1016/j.phymed.2017.08.027. Epub 2017 Sep 21. PMID: 29655675.
12: Zhong W, Wu Z, Chen N, Zhong K, Lin Y, Jiang H, Wan P, Lu S, Yang L, Liu S. Eupatilin Inhibits Renal Cancer Growth by Downregulating MicroRNA-21 through the Activation of YAP1. Biomed Res Int. 2019 Apr 24;2019:5016483. doi: 10.1155/2019/5016483. PMID: 31179326; PMCID: PMC6507163.
13: Li Y, Ren R, Wang L, Peng K. Eupatilin alleviates airway remodeling via regulating phenotype plasticity of airway smooth muscle cells. Biosci Rep. 2020 Jan 31;40(1):BSR20191445. doi: 10.1042/BSR20191445. PMID: 31913462; PMCID: PMC6970064.
14: Lee HY, Nam Y, Choi WS, Kim TW, Lee J, Sohn UD. The hepato-protective effect of eupatilin on an alcoholic liver disease model of rats. Korean J Physiol Pharmacol. 2020 Sep 1;24(5):385-394. doi: 10.4196/kjpp.2020.24.5.385. PMID: 32830145; PMCID: PMC7445478.
15: Lee CJ, Hong SH, Yoon MJ, Lee KA, Choi DH, Kwon H, Ko JJ, Koo HS, Kang YJ. Eupatilin treatment inhibits transforming growth factor beta-induced endometrial fibrosis in vitro. Clin Exp Reprod Med. 2020 Jun;47(2):108-113. doi: 10.5653/cerm.2019.03475. Epub 2020 May 28. PMID: 32460455; PMCID: PMC7315855.
16: Kim J, Kim Y, Yi H, Jung H, Rim YA, Park N, Jung SM, Park SH, Ju JH. Eupatilin ameliorates collagen induced arthritis. J Korean Med Sci. 2015 Mar;30(3):233-9. doi: 10.3346/jkms.2015.30.3.233. Epub 2015 Feb 16. PMID: 25729243; PMCID: PMC4330475.
17: Li F, Tao Y, Qiao Y, Li K, Jiang Y, Cao C, Ren S, Chang X, Wang X, Wang Y, Xie Y, Dong Z, Zhao J, Liu K. Eupatilin inhibits EGF-induced JB6 cell transformation by targeting PI3K. Int J Oncol. 2016 Sep;49(3):1148-54. doi: 10.3892/ijo.2016.3600. Epub 2016 Jul 4. PMID: 27573489.
18: Qiao HB, Li J, Lv LJ, Nie BJ, Lu P, Xue F, Zhang ZM. Eupatilin inhibits microglia activation and attenuates brain injury in intracerebral hemorrhage. Exp Ther Med. 2018 Nov;16(5):4005-4009. doi: 10.3892/etm.2018.6699. Epub 2018 Sep 5. PMID: 30344678; PMCID: PMC6176204.
19: Lee JY, Bae H, Yang C, Park S, Youn BS, Kim HS, Song G, Lim W. Eupatilin Promotes Cell Death by Calcium Influx through ER-Mitochondria Axis with SERPINB11 Inhibition in Epithelial Ovarian Cancer. Cancers (Basel). 2020 Jun 3;12(6):1459. doi: 10.3390/cancers12061459. PMID: 32503295; PMCID: PMC7353024.
20: Park JY, Park DH, Jeon Y, Kim YJ, Lee J, Shin MS, Kang KS, Hwang GS, Kim HY, Yamabe N. Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling. Bioorg Med Chem Lett. 2018 Oct 15;28(19):3150-3154. doi: 10.1016/j.bmcl.2018.08.034. Epub 2018 Aug 28. Erratum in: Bioorg Med Chem Lett. 2019 Jan 15;29(2):347. PMID: 30177376.
